Shruti Trehan
Hematology & Oncology · Canton, OHNPI 1376512046
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $35,118 of the $56,796 with a category attached, or 61.8%. 36 manufacturers reported payments, led by AstraZeneca at 43.1% of the total. Reporting peaked in 2021 at $27,225 and has fallen 99.8% since, to $48 in 2023. Among hematology & oncology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 172 payments — averaging $330.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$24K
- Daiichi Sankyo Inc.$15K
- Lexicon Pharmaceuticals, Inc.$7K
- Eisai Inc.$3K
- Sanofi$3K
- Puma Biotechnology, Inc.$1K
- plus $3K from 30 others
Across 41 payments — averaging $6958.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$154K
- Astrazeneca UK Limited$67K
- Genentech, Inc.$32K
- Amgen$30K
- Novartis$2K
- E.r. Squibb & Sons, L.L.C.$17
What the payments were for
- Consulting fees$35,11862%
- Speaking & faculty fees$18,02032%
- Travel & lodging$5961%
- Food & beverage$2,8725%
- Education$1910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 27 | $24,498 |
| Daiichi Sankyo Inc. | 11 | $15,063 |
| Lexicon Pharmaceuticals, Inc. | 8 | $7,019 |
| Eisai Inc. | 4 | $3,275 |
| Sanofi | 4 | $3,207 |
| Puma Biotechnology, Inc. | 2 | $1,015 |
| EMD Serono, Inc. | 1 | $500 |
| Merck | 20 | $274 |
| Genentech USA, Inc. | 11 | $250 |
| Lilly USA, LLC | 13 | $217 |
| E.r. Squibb & Sons, L.L.C. | 4 | $145 |
| Pharmacyclics LLC, An Abbvie Company | 8 | $134 |
| Incyte Corporation | 3 | $129 |
| Bristol Myers Squibb | 7 | $128 |
| Novartis | 8 | $123 |
| Amgen | 5 | $94 |
| Jazz Pharmaceuticals Inc. | 4 | $76 |
| Tesaro, Inc. | 4 | $61 |
| Myovant Sciences Inc. | 2 | $50 |
| Medtronic | 1 | $48 |
| Seagen Inc. | 3 | $47 |
| Boehringer Ingelheim | 2 | $46 |
| Beigene USA, Inc. | 1 | $45 |
| Agios Pharmaceuticals, Inc. | 1 | $43 |
| Sanofi Pasteur Inc. | 2 | $40 |
| Astellas Pharma US Inc | 2 | $38 |
| Gilead | 2 | $36 |
| Bayer | 2 | $32 |
| GSK | 2 | $32 |
| Pfizer | 2 | $25 |
| Janssen Scientific Affairs, LLC | 1 | $21 |
| Heron Therapeutics, Inc. | 1 | $21 |
| AbbVie | 1 | $18 |
| Exelixis Inc. | 1 | $16 |
| Blueprint Medicines Corporation | 1 | $15 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$56,796 in reported general payments places this provider in the 90th percentile of 450 hematology & oncology providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 12 | $259 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Canton
- Hillard LazarusCleveland$2M
- Kasra KaramlouSandusky$1.8M
- David WaterhouseCincinnati$1.3M
- Taral PatelColumbus$888K
- Tarek ChidiacColumbus$765K
- Saulius GirniusMontgomery$707K
- Ronald BukowskiCleveland$594K
- Balazs HalmosCleveland$568K
- Jorge GarciaCleveland$513K
- Alejandro CalvoKettering$463K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.